Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)

China · Delayed Price · Currency is CNY

50.02

-1.12 (-2.19%)

Jun 10, 2026, 3:00 PM CST

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Pharmacy Research Services	338.48M	558.68M	568.60M	441.90M	-
Pharmacy Research Services Growth	-39.41%	-1.74%	28.67%	-	-
Clinical Trials and Bioanalytical Services	522.56M	511.65M	362.39M	234.50M	-
Clinical Trials and Bioanalytical Services Growth	2.13%	41.19%	54.54%	-	-
Innovative Drugs and Improved New Drugs	248.36M	-	-	-	-
Intellectual Property Licensing	100.00M	-	-	-	-
Equity Sharing	10.94M	6.53M	-	-	-
Equity Sharing Growth	67.44%	-	-	-	-
Total	1.22B	1.08B	930.98M	676.39M	-
Total Growth	13.32%	15.67%	37.64%	-	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
China	1.22B	1.08B	932.12M	676.61M	493.65M
China Growth	13.33%	15.70%	37.76%	37.06%	42.12%
Total	1.22B	1.08B	932.12M	676.61M	493.65M
Total Growth	13.33%	15.70%	37.76%	37.06%	42.12%

Source: S&P Global Market Intelligence.